EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling

William Middlezong, Victoria Stinnett iD, Michael Phan, Brian Phan, Laura Morsberger, Melanie Klausner, Jen Ghabrial iD, Natalie DeMetrick, Jing Zhu, Trisha James, Aparna Pallavajjala, Christopher D Gocke iD und 2 weitere

Biomolecules · 2024

DOI: 10.3390/biom14121595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von William Middlezong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Nanopore Sequencing, CRISPR-Cas Systems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johns Hopkins Institute for Clinical and Translational Research (ICTR), NCATS NIH HHS, ICTR’s Accelerated Translational Incubator Pilot (ATIP) grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute promyelocytic leukemia (APL) accounts for approximately 10–15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly reverses coagulopathy. The PML::RARA fusion is a hallmark of APL and its rapid identification is essential for rapid initiation of specific treatment to prevent early deaths from coagulopathy and bleeding and optimize patient outcomes. Given limitations and long turnaround time of current gene fusion diagnostic strategies, we have developed a novel amplification-free nanopore sequencing-based approach with low cost, easy setup, and fast turnaround time. We termed the approach CRISPR/Cas9-enriched nanopore sequencing with adaptive sampling (CENAS). Using CENAS, we successfully sequenced breakpoints of typical and atypical PML::RARA fusions in APL patients. Compared with the standard-of-care genetic diagnostic tests, CENAS achieved good concordance in detecting PML::RARA fusions in this study. CENAS allowed for the identification of sequence information of fusion breakpoints involved in typical and atypical PML::RARA fusions and identified additional genes (ANKFN1 and JOSD1) and genomic regions (13q14.13) involving the atypical fusions. To the best of our knowledge, involvements of the ANKFN1 gene, the JOSD1 gene, and the 13q14.13 genomic region flanking with the SIAH3 and ZC3H13 genes have not been reported in the atypical PML::RARA fusions. CENAS has great potential to develop as a point-of-care test enabling immediate, low-cost bedside diagnosis of APL patients with a PML::RARA fusion. Given the early death rate in APL patients still reaches 15%, and ~10% of APL patients are resistant to initial therapy or prone to relapse, further sequencing studies of typical and atypical PML::RARA fusion might shed light on the pathophysiology of the disease and its responsiveness to treatment. Understanding the involvement of additional genes and positional effects related to the PML and RARA genes could shed light on their role in APL and may aid in the development of novel targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteOncogene Proteins, FusionNanopore SequencingCRISPR-Cas SystemsHumansRetinoic Acid Receptor alphaPromyelocytic Leukemia Protein

Stichwörter der Autor:innen

CRISPR/Cas9PML::RARA fusionsacute promyelocytic leukemiaadaptive samplingnanopore sequencing

Substanzen

Oncogene Proteins, Fusionpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinRetinoic Acid Receptor alphaRARA protein, humanPromyelocytic Leukemia Protein

Autor:innen und Institutionen

  • Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Department of Biology, The College of William and Mary, Williamsburg, VA 23186, USA.
  • Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.

ORCID-Profile: Victoria Stinnett, Jen Ghabrial, Christopher D Gocke, Ying S Zou

Förderung

  • Johns Hopkins Institute for Clinical and Translational Research (ICTR)
  • NCATS NIH HHS
  • ICTR’s Accelerated Translational Incubator Pilot (ATIP) grant

Zitieren

APA

Middlezong, W., Stinnett, V., Phan, M., Phan, B., Morsberger, L., Klausner, M., Ghabrial, J., DeMetrick, N., Zhu, J., James, T., Pallavajjala, A., Gocke, C. D., Baer, M. R., & Zou, Y. S. (2024). Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling. Biomolecules. https://doi.org/10.3390/biom14121595

Vancouver

Middlezong W, Stinnett V, Phan M, Phan B, Morsberger L, Klausner M, et al. Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling. Biomolecules. 2024. doi:10.3390/biom14121595

BibTeX
@article{Middlezong2024,
  author = {Middlezong, William and Stinnett, Victoria and Phan, Michael and Phan, Brian and Morsberger, Laura and Klausner, Melanie and Ghabrial, Jen and DeMetrick, Natalie and Zhu, Jing and James, Trisha and Pallavajjala, Aparna and Gocke, Christopher D and Baer, Maria R and Zou, Ying S},
  title = {Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14121595}
}
Kostenlos starten →